ESH Day 4

Clinical Practice Update – What Should We Do Di erently Now

by Prateek Chopra | June 20, 2026 | Cardiology Conferences | ESH 2026 Study Background: Despite established guidelines, hypertension remains poorly controlled globally, particularly in primary care. Barriers to guideline implementation include structural, behavioral, and communication challenges across healthcare systems. This session outlined practical strategies to transform everyday hypertension management using insights from clinicians across Europe. Methodology & Framework: Key Insights: […]

Clinical Practice Update – What Should We Do Di erently Now Read Post »

Leave a Comment / ESH Day 4 / / / , , , ,

Interventional Treatment of Hypertension: From Renal Denervation to the Next Wave

by Prateek Chopra | June 20, 2026 | Cardiology Conferences | ESH 2026 Therapeutic Context: Renal denervation (RDN) is emerging as a third pillar of hypertension management, alongside lifestyle modification and pharmacotherapy, for selected patients with uncontrolled or resistant hypertension. The clinical question is whether RDN provides benefits beyond BP reduction and whether a single intervention is sufficient for BP control.

Interventional Treatment of Hypertension: From Renal Denervation to the Next Wave Read Post »

Leave a Comment / ESH Day 4 / / / , , , ,

Device Innovations: The Next Generation of Cardiovascular Technologies

by Prateek Chopra | June 19, 2026 | Cardiology Conferences | ESH 2026 Study Background: Advances in cardiology are driving novel devices and techniques for cardiovascular disease management. Emerging technologies aim to improve monitoring, diagnostics, and personalized care, particularly in hypertension and cardiovascular risk assessment. Key Innovations: Cuffless and Wearable Blood Pressure Monitoring: Rings, watches, and wristbands enable continuous, convenient out-of-office

Device Innovations: The Next Generation of Cardiovascular Technologies Read Post »

Leave a Comment / ESH Day 4 / / / , , , ,

From Bench to Bedside: Translational Advances in Cardiovascular Disease

by Prateek Chopra | June 19, 2026 | Cardiology Conferences | ESH 2026 Clinical Context: While the gut microbiome may influence blood pressure regulation, population-based evidence does not demonstrate a consistent link with future hypertension. Translational research is advancing our understanding of neuro-immune, inflammatory, and hormonal mechanisms in cardiovascular disease. Key Mechanistic Insights: Gut Microbiome: Rigorous sample collection, confounder control, and

From Bench to Bedside: Translational Advances in Cardiovascular Disease Read Post »

Leave a Comment / ESH Day 4 / / / , , , ,

Differential Use of Diuretics in Hypertensive Patients with Chronic Kidney Disease (CKD): The Joint ESH–ERA Session

by Prateek Chopra | June 18, 2026 | Cardiology Conferences | ESH 2026 Clinical Background: Hypertension in chronic kidney disease (CKD) arises from sodium retention, RAAS activation, sympathetic overactivity, and endothelial dysfunction. High dietary salt intake accelerates CKD progression via proteinuria and glomerular hyperfiltration, making diuretics central to hypertension management. Evidence & Guideline Recommendations: Treatment-Resistant Hypertension: Clinical Implications: A tailored, CKD

Differential Use of Diuretics in Hypertensive Patients with Chronic Kidney Disease (CKD): The Joint ESH–ERA Session Read Post »

Leave a Comment / ESH Day 4 / / / , , , ,

Use of Renin-Angiotensin System Inhibitors in Patients with CKDStage 4 and 5: What to Do and What Not to Do

by Prateek Chopra | June 18, 2026 | Cardiology Conferences | ESH 2026 Clinical Rationale: RAS inhibitors (RASi) reduce CKD progression and cardiovascular risk but are frequently discontinued in patients with eGFR <30 ml/min/1.73m² due to concerns about hyperkalemia, hypotension, and renal function deterioration. Evidence Review: Management of Hyperkalemia: Consequences of RASi Discontinuation: Clinical Implications: In patients with CKD G4–G5, RASi

Use of Renin-Angiotensin System Inhibitors in Patients with CKDStage 4 and 5: What to Do and What Not to Do Read Post »

Leave a Comment / ESH Day 4 / / / , , , ,

When and How to Use 24-h Ambulatory Blood PressureMonitoring in Patients with CKD

by Prateek Chopra | June 17, 2026 | Cardiology Conferences | ESH 2026 Study Background: Chronic kidney disease (CKD), defined as abnormalities of kidney structure or function persisting ≥3 months, is a growing global burden, ranking as the 10th leading cause of death and a major contributor to cardiovascular mortality. Hypertension is highly prevalent in CKD, and patients frequently exhibit true

When and How to Use 24-h Ambulatory Blood PressureMonitoring in Patients with CKD Read Post »

Leave a Comment / ESH Day 4 / / / , , , ,

Blood Pressure Lowering Effects of Pharmacological and Device Based Interventions for Resistant Hypertension: A Systematic Review and Meta-Analysis

by Prateek Chopra | June 17, 2026 | Cardiology Conferences | ESH 2026 Clinical Context: Resistant hypertension (RHTN) remains a major clinical challenge. This systematic review and meta-analysis evaluated the blood pressure-lowering efficacy and hypertension control rates achieved after the addition of pharmacological or device-based interventions (e.g., renal denervation, RDN) in patients with true RHTN. Study Design: Key Findings: Clinical Implications:

Blood Pressure Lowering Effects of Pharmacological and Device Based Interventions for Resistant Hypertension: A Systematic Review and Meta-Analysis Read Post »

Leave a Comment / ESH Day 4 / / / , , , ,

Personalised Prevention for Patients with Dyslipidaemia, Hypertension, and Elevated hs-CRP: The Key to Optimal Cardiovascular Care

by Prateek Chopra | June 16, 2026 | Cardiology Conferences | ESH 2026 Background and Rationale: Cardiovascular disease (CVD) prevention is increasingly shifting from a population-based model to a personalized approach that integrates genetic risk, traditional risk factors, and inflammatory biomarkers. Precision medicine can enhance prevention strategies in patients with dyslipidemia, hypertension, and elevated inflammatory burden. Genetic Risk Assessment: Hemodynamic-Guided Hypertension

Personalised Prevention for Patients with Dyslipidaemia, Hypertension, and Elevated hs-CRP: The Key to Optimal Cardiovascular Care Read Post »

Leave a Comment / ESH Day 4 / / / , , , ,

2026 Lipid-Management Guidelines for High-Risk Patients:Cutting-Edge Strategies to Halt Atherosclerosis Progression

by Prateek Chopra | June 16, 2026 | Cardiology Conferences | ESH 2026 Therapeutic Challenge: Despite advances in lipid-lowering therapy (LLT), guideline-recommended LDL-C targets remain poorly achieved among patients with established atherosclerotic cardiovascular disease (ASCVD). Residual cardiovascular risk persists, highlighting the need for earlier and more intensive lipid-lowering strategies. Study Evidence: Guideline Recommendations: Emerging Clinical Evidence: The 2026 lipid-management paradigm emphasizes

2026 Lipid-Management Guidelines for High-Risk Patients:Cutting-Edge Strategies to Halt Atherosclerosis Progression Read Post »

Leave a Comment / ESH Day 4 / / / , , , ,
Scroll to Top